Smit HJM, Aerts J, van den Heuvel M, et al. - From the initial introduction of checkpoint inhibitors in the Netherlands, central registration of the patients is done. Educational programs and quality control are provided under the supervision of the Dutch Society of Chest Physicians (NVALT). Researchers here performed a comparison of the largest immunotherapy providing hospitals with hospitals that provided less checkpoint inhibitors as marker of experience. Further, they performed an assessment of patients' characteristics, treatment and side effects, response rate and survival. They identified registration of a total of 2,676 patients and evaluated 2,302 with follow up data. The analysis revealed no change in the quality of care between hospitals with the introduction of immunotherapy. Immunotherapy was provided in routine practice to patients underrepresented in trials. Survival of patients with brain metastases was as long as of those without this disorder. Longer survival was reported for patients with selected autoimmune disorders.